Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Source :: GlobeNewswire. December 13, 2023
Publication Year :: 2023
Abstract: Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY(TM) (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas [...]

Subjects :: Vertex Pharmaceuticals Inc. -- Licensing agreements
Editas Medicine Inc. -- Licensing agreements
Sickle cell anemia
Biotechnology industry -- Licensing agreements
Drugs -- Licensing agreements
Pharmaceutical industry -- Licensing agreements
Company licensing agreement
Banking, finance and accounting industries
Business

Tools